Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Luseogliflozin and Dietary GI/Carbohydrate in T2DM
NCT02500186Completed
- Sponsor
- Kansai Electric Power Company Hospital
- Start
- May 2015
- Primary completion
- Dec 2015
- Modality
- Small Molecules
01
Overview
Randomised, open-label trial of luseogliflozin in type 2 diabetes mellitus (T2DM), sponsored by Kansai Electric Power Company Hospital. Started May 2015; status: completed.
02
Drugs
luseogliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02500186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02500186.